

17th World Congress on Biomarkers, Cancer Therapy and Clinical Research

September 23, 2022 | Webinar

ISSN: 2155-9929

For metastatic renal cell carcinoma: Pazopanib A case report.

ABSTRACT:

Malignant renal cell carcinoma (RCC) account for 2-3% of cancer incidence and results in over 100 000 worldwide deaths annually. Metastatic renal cell carcinoma has historically been refractory to cytotoxic and hormonal agent; only interleukin 2 and interferon alpha provide response in a minority of patient. We present case of metastatic renal cell cancer treated with pazopanib with good CR (complete response).

Pazopanib is oral an angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor and c-kit. is approved for the first line treatment of patients with metastatic renal cell carcinoma (mRCC).

Case over view:

Initial presentation:

A 35 -year- old female presents with sudden onset lower back pain with hematuria, no h/o DM or hypertension,

Clinical work up:

Chest/abdominal/pelvic CT showed: A right -sided 2.33 cmx 1.9 cm renal mass. Partial right nephrectomy biopsy confirmed renal cell carcinoma (clear cell variant).

Treatment and follow-up:

The patient underwent right partial nephrectomy; surgery was well-tolerated, fellow up at 3, 6, months were unremarkable. At 9 months the patient developed disease with multifocal diseased in her lung; stage IV. Labs with normal limits, ECOG0. She started treatment on sunitinib for 3weeks, not tolerated with sever gastritis and hemostasis and increase liver enzymes, stop treatment. she started treatment on pazopanib (400mgx2 tablets); well -tolerated for two years, achieved CR pazopanib provide equivalent anti-tumor effectiveness in treatment of mRCC.

Keywords:

metastatic RCC, pazopanib, response, Survival

Biography:

Dr. Amani Saleh Hadi Saeed, M.B ,B.CH.MSc. is a Specialist of Clinical Oncology and Nuclear Medicine at National Oncology Center-Aden and she is the Head of Health Education Unit for Arab Council of Academic and Competencies-branch of Yemen. She is the Advisor to the Policy and Technical support Unit, Republic of Yemen-Ministry of Public Health and Population. She has a Membership in Union of Afro-Asia universities. She is a part of the Editorial board in case reports and Research practice in Medicine Journal (CRRPM).

r_332@yahoo.com

Dr. Amani Saleh Hadi Saeed

Specialist of clinical oncology, Arab
council National oncology
center –Aden, Yemen.

Received: July 25, 2022; **Accepted:** July 26, 2022; **Published:** September 23, 2022